Orion is developing an immuno-oncology (IO) drug discovery platform in the national research and innovation consortium Cancer IO

NEXT STORY
Timber Pharmaceuticals Announces Appointment of Dr. Gianluca Pirozzi and Edward J. Sitar to Board of Directors
PREV STORY
Myriad Genetics Announces Publication of a Prospective Clinical Study of the EndoPredict® Test in Women with Early-Stage Breast Cancer
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

Inovio Pharmaceuticals to Report First Quarter 2016 Financial Results May 9, 2016

PLYMOUTH MEETING, Pa., April 26, 2016 (GLOBE NEWSWIRE) -- Inovio Pharmaceuticals, Inc. (NASDAQ:INO) announced ...

author_avatar
NASDAQ Market News

Neovacs announces its clinical advisory board meeting to design the Phase III Study for IFNalpha Kinoide in lupus – Paris February 11th

PRESS RELEASE · PRESS RELEASE · PRESS RELEASE NEOVACS ANNOUNCES ITS CLINICAL ADVISORY BOARD ...

author_avatar
NASDAQ Market News

Fennec Announces Positive Results From Phase 3 SIOPEL 6 Study on PEDMARK™ (sodium thiosulfate) Presented at the 49th Congress of the International Society of Pediatric Oncology (SIOP) 2017 Meeting

Study met primary endpoint (p=0.0033) Significant reduction in cisplatin induced hearing loss without any ...

author_avatar
NASDAQ Market News